As indicated by Elens et al., decreased CYP3A4 metabolism due to CYP3A4∗22 could be demonstrated in cancer patients, as determined by midazolam and erythromycin metabolism (Elens et al., 2013b). The gene discussed is CYP3A4; the disease is cancer.